

Supplementary Materials for
**Nitrosylation of GAPDH augments pathological tau acetylation upon
exposure to amyloid- β**

Tanusree Sen, Pampa Saha, Nilkantha Sen*

*Corresponding author. Email: senn@pitt.edu

Published 20 March 2018, *Sci. Signal.* **11**, eaao6765 (2018)
DOI: 10.1126/scisignal.aao6765

This PDF file includes:

- Fig. S1. Quantitative analysis of tau acetylation in vitro and in vivo.
- Fig. S2. Quantitative analysis of GAPDH nitrosylation after A β_{1-42} administration.
- Fig. S3. Quantitative analysis of transnitrosylation of SIRT1 and its effect on tau acetylation.
- Fig. S4. Quantitative analysis of tau acetylation after inhibition of GAPDH nitrosylation.




Fig. S1. Quantitative analysis of tau acetylation in vitro and in vivo. (A) Quantitative analysis of immunoblotting for acetylated tau abundance in primary cortical neurons treated with Aβ₁₋₄₂ for 24 hours with or without L-NAME. (B) Confocal microscopy analysis of the fold change in the red fluorescent intensity of acetylated tau. (C) Immunoblotting analysis of the fold change in acetylation of tau at Lys²⁸⁰ in cortical neurons from nNOS^{+/+} and nNOS^{-/-} mice after administration of Aβ₁₋₄₂ with or without L-NAME. (D) Confocal microscopy analysis of the fold change in the red fluorescent intensity indicating acetylation of tau in cortical neurons from nNOS^{+/+} and nNOS^{-/-} mice. (E) Immunoblotting analysis of the fold change in tau acetylation at Lys²⁸⁰ in cortical neurons from nNOS^{+/+} and nNOS^{-/-} mice after administration of Aβ₁₋₄₂. All data are mean ± S.E.M, n=8-10, except for (C) (n=3-5); *p<0.05, **p<0.001 by student's *t*-test.




Fig. S2. Quantitative analysis of GAPDH nitrosylation after Aβ₁₋₄₂ administration. (A) Quantitative analysis of immunoblotting for the fold change in the abundance of nitrosylated GAPDH in post-mortem cortical brain tissue samples from control and AD patients. (B) Quantitative analysis of immunoblotting for the fold change in the acetylation of tau and H3 in cultured cortical neurons after overexpression of either HA-GAPDH or HA-GAPDH-K160R. (C) Quantitative analysis of immunoblotting for the Fold change in tau acetylation, assessed by red fluorescence intensity in confocal microscopy, in the cortex of mice overexpressing HA-GAPDH or HA-GAPDH-K160R and injected with Aβ₁₋₄₂. (D) Fold change in tau acetylation at Lys²⁸⁰ after administration of Aβ₁₋₄₂ to isolated cortical neurons transfected with control or p300-targeted siRNA (RNAi). All data are mean ± S.E.M., n= 5-7; *p<0.05, **p<0.001 by student's *t*-test.




Fig. S3. Quantitative analysis of transnitrosylation of SIRT1 and its effect on tau acetylation. (A) Quantification of co-immunoprecipitation assays to measure the interaction between tau and SIRT1 in the cortex of nNOS^{+/+} and nNOS^{-/-} mice, presented as fold change relative to controls. (B) Quantification of immunoblotting for the fold change in SIRT1 nitrosylation in the cortex of nNOS^{+/+} and nNOS^{-/-} mice injected with HA-GAPDH or HA-GAPDH-K160R then Aβ₁₋₄₂. (C) Quantification of co-immunoprecipitations assessing the interaction between tau and SIRT1 in cultured primary cortical neurons transfected with SIRT1 or SIRT1-C387/390S. (D) Quantification of immunoblotting for the fold change in acetylation of tau and H3 in cells described in (C). (E) Fold change in red fluorescence intensity, indicating tau acetylation, after overexpression of either SIRT1 or SIRT1-C387/390S in the cortex. (F) Quantification of immunoblotting for the fold change in tau acetylation in cultured primary cortical neurons after administration of either control or HDAC6 siRNA. All data are mean ± S.E.M., n=8-10 (A) or 5-7 (B-F); *p<0.05, **p<0.001 by student's *t*-test.




Fig. S4. Quantitative analysis of tau acetylation after inhibition of GAPDH nitrosylation. (A) Quantification of co-immunoprecipitation assays, presented as fold change in tau acetylation at Lys²⁸⁰ in cortical lysates from mice that were intracortically injected with HA-GAPDH or HA-GAPDH-K160R then $A\beta_{1-42}$. (B) Quantification of confocal microscopy analysis as fold change in red fluorescence intensity, indicating acetylated tau, in the cortex after overexpression of either HA-GAPDH or HA-GAPDH-C150S then $A\beta_{1-42}$. (C) Quantification of confocal microscopy analysis as fold change in red fluorescence intensity, indicating acetylated tau, in the cortex after treatment with CGP3466B then $A\beta_{1-42}$. (D and E) Quantification of blotting analysis GAPDH nitrosylation (D) and tau acetylation (E) in cortical lysates from mice treated with CGP3466B (2.5 mg/kg) then $A\beta_{1-42}$. All data are mean \pm S.E.M., n=5-7; *p<0.05, student's *t*-test.